United States: New York

Firms: litigation

Firms: prosecution

Firms: transactions

Alston & Bird LLP

Alston & Bird’s experience in prosecution, post-grant and litigation settings grants it a panoramic perspective of the patent landscape, which it capitalises on through a collaborative approach to render holistic solutions to its clients. Drilling deeper into the practice reveals pharmaceutical and life sciences patent litigation as one of its strongest suits, particularly for the dynamic crew in New York fronted by Natalie Clayton and Thomas Parker. Setting an excellent example in terms of trial skill, commerciality and client service, Clayton is the resolute leader of the team. Alongside colleagues in Atlanta, she is currently representing Merial in a licensing dispute regarding its most valuable formulation patent covering Frontline Plus – the first billion-dollar animal health product. Parker has litigated extensively under the Hatch-Waxman Act and has a fine-grained knowledge of the Biologics Price Competition and Innovation Act; the former drug company research scientist also taps into deep Food and Drug Administration (FDA) regulatory expertise.

Arnold & Porter Kaye Scholer LLP

Steeped in the life sciences, Arnold & Porter Kaye Scholer holds it down for a coveted selection of industry-leading pharmaceutical and biotech clients. Demand for the set’s honed and sophisticated trial representation is high when there is hundreds of millions of dollars at stake; New Yorkers Aaron Stiefel, Daniel DiNapoli, David Barr and Daniel Reisner are lawyers you can trust to come through with a resonant performance in times of need. Barr has been the go-to guy for Pfizer and Novartis over many years and is very hand-on; Stiefel’s writing and regulatory skills are some of the best in the business. DiNapoli is hailed for his problem-solving ingenuity – there is no such thing as a litigation roadblock to him. While “consummate pro” Reisner is a “sharp and intuitive litigator who is really quick on his feet”; he is currently teamed up with Barr, California partner Deborah Fishman and DC’s Matthew Wolf to defend Sanofi and Regeneron against a patent enforcement action brought by Amgen on patents relating to anti-PCSK9 antibodies asserted against Sanofi and Regeneron’s Praluent therapeutic.

Baker Botts LLP

Baker Botts consistently fields one of the strongest multi-service patent practices of any general commercial firm and, as a result, cultivates a complete understanding of its clients’ innovations and businesses. Thriving in this environment is protean professional Paul Ragusa who, this year, is listed on each of the IAM Patent 1000’s prosecution, litigation and transactions tables. His versatility manifests itself in his university work; he assists Columbia University with respect to the development and management of its worldwide physical and life sciences patent portfolio and licensing matters – and has conducted trial work for it – and also undertakes myriad prosecution and transactional tasks for the University of Pennsylvania. Recently, Ragusa has been burnishing his post-grant credentials by acting for pharmaceutical companies and building on his expert knowledge of SEPs and antitrust law. Also making it onto multiple tables (for prosecution and transactions) is Daniel Hulseberg, a master patent strategist and deal negotiator for companies in the medical device, healthcare, energy and financial sectors. An important storyline in Baker Botts’ narrative of recent years is the firm’s emergence as a leading force at the International Trade Commission (ITC). Significant contributions in this domain come from Robert Maier, Neil Sirota and Robert Scheinfeld who have recently been representing Fujifilm in four highly nuanced and commercially vital ITC cases against Sony. However, the trio are not easy to pigeonhole because their practices extend into counselling and prosecution work too.

Cravath, Swaine & Moore LLP 

For brain-bendingly complex must-win company suits, it is hard to find a better firm than Cravath. When patent, antitrust, breach of contract, licensing and other issues snarl together to create Gordian knots, the Cravath lawyers patiently untangle them through a combination of incredible intellectual horsepower, diligence, exceptional teamwork and dedication. Putting all this on display when representing Qualcomm against Apple are Evan R Chesler, Richard J Stark and David R Marriott, three seasoned trial lawyers with razor-sharp advocacy skills. Meanwhile, Keith R Hummel has been absolutely tearing it up of late; for example, at the culmination of a six-day jury trial in Delaware, he got a unanimous decision in a matter of minutes for DRI against Glaxo Group and Human Genome Sciences Inc in a tough patent licensing dispute – we are talking best trial advocate in the world-type stuff here; in addition, he has been representing Amgen against AbbVie regarding a biosimilar to the latter’s biologic drug Humira. He is also hugely respected by his opponents: “Keith is a terrific trial lawyer whose word is his bond.” As with the Amgen work, Hummel frequently links up with David Greenwald, the recipient of the 2018 Client Choice Award for litigation in New York. The Cravath professionals demonstrate complete composure when handling transactional matters that are of critical importance to industry leaders. The volume of deals carried out by the firm – and the amount and significance of the intellectual property in them – just keeps on growing, but this is no problem for David J Kappos. Advising Alere on its $8 billion sale to Abbott Laboratories; AXA on its $15.3 billion acquisition of XL Group; and GKN on the proposed $6.1 billion combination of its Driveline business with Dana Incorporated are just some of the things Kappos has been up to recently. “David’s many years in-house are of great value, since he innately understands the complexities of patent transactions. He maintains a calm and professional demeanour in negotiations and he is fantastic with associates, which is great to see; he provides them with unbeatable training.” Kappos’s authoritative engagement on privacy issues has also been a notable highlight, which continues to be a big story in intellectual property; commentators point out that, “in terms of patent policy expertise he has no peer in the market”.

Dechert LLP

Dechert has made some impressive talent aggregation moves in New York lately, landing Simpson Thacher lawyer Noah Leibowitz and Hughes Hubbard partner Stephen Rabinowitz, both vastly experienced life sciences litigators. Garnering particular praise from Dechert’s client references, “Noah is a brilliant strategist who absorbs complex business and technical details at lightning speed. His attention to detail and communication skills are superb and he anticipates and overcomes obstacles before they even present themselves. He’s one of the very best.” When you factor in prosecution and counselling partner Samuel Abrams, Dechert looks set to become one of New York’s most dynamic life sciences firms on both sides of the contentious/non-contentious divide.

Desmarais LLP 

Virtually matchless as a trial boutique, Desmarais has been securing outstanding results lately. To give a sample, in a Delaware jury trial, it led IBM to an $82.5 million victory over Groupon, which was found to have wilfully infringed all four patents in suit; it also secured a settlement for Cisco Systems under the terms of which Arista Networks agreed to pay the company $400 million following its successful dismissal of half of Arista’s antitrust claims against Cisco in 2017; and it won an infringement verdict for Intellectual Ventures against Toshiba. The firm “consistently delivers brilliant outcomes” such as these thanks to its deep bench of trial lawyers. Some of the best feedback is reserved for John M Desmarais and Paul A Bondor, who linked up for Cisco: “John is the best of the best in patent litigation and one of the rare litigators who gives his honest opinion on your chances of success. He has vast courtroom experience but has also trained his junior lawyers to perform at the highest level at trial too. Responsive, engaged and attentive, Paul is exceptionally hands-on for such a senior lawyer. He has excellent litigation instincts and provides sound and thoughtful advice on complex matters.” Alan S Kellman and Jonas R McDavit, who joined forces for Intellectual Ventures, are also “top-tier in terms of quality”. Several sources highlight the firm’s innovative and flexible approach to fee arrangements as a major magnet; the team’s economic incentives are neatly aligned with its clients’ desire to get results.

Fenwick & West LLP

Debuting in the IAM Patent 1000 New York section this year, Fenwick & West has made impressive strides since it opened its local office in the summer of 2016. For one thing, Daniel Brownstone has continued to acquit himself with distinction as a confidant to top innovators in the computer science and high-tech domains; for another, the firm scored a coup in June 2018 when it recruited three acclaimed patent litigators from White & Case in Jeffrey Oelke, Kevin McGann and James Trainor. Oelke brings superb life sciences litigation expertise to the practice; McGann has slotted in well given his synergistic expertise in the high-tech realm; and deploying artfully across all technical domains, Trainor is a “superb litigation strategist” and “excellent courtroom advocate who knows how to weave a convincing story around dense legal and technical issues”. The continued growth of this elite Silicon Valley outfit in New York will be one of the most exciting things for legal market observers to watch in the coming year.

Fish & Richardson

Whether you are looking at volume of cases or quality of outcomes, Fish is operating at a stratospheric level in patent litigation. In fact, it is the top player in all areas of patent practice and is a leading name for post-grant representation and prosecution to boot. For a litigator in New York look to Michael Zoppo, an experienced first-chair trial lawyer with a glittering track record representing insurance companies, banks and exchanges in commercially consequential patent duels. His recent highlights include winning a Federal Circuit case for diversified financial services company United Services Automobile Association. For patent procurement, the person that high-tech companies should have on speed dial is Samuel Borodach; his dual-prosecution and litigation experience lends itself well in inter partes review work and sets him apart as a strategic overseer. “Sam communicates extremely well and gives you complete confidence that he fully understands your inventions and the product applications they are destined for. He is very responsive and works fast so that your competitive advantage is protected at all times.” Anchoring the local life sciences practice, genetics PhD Jack Brennan is an opinion giver par excellence and experienced due diligence and prosecution expert. As one source enthuses: “Jack operates as a valued member of our internal group and gets deeply involved at a strategic level. His team is top notch and functions with exceptional efficiency.”

Fox Rothschild LLP

Fox Rothschild makes an excellent addition to the IAM Patent 1000’s New York prosecution rankings for 2019 – with Janet MacLeod and Deborah Somerville in the fold, it is a premier destination for biopharmaceutical companies in need of portfolio management support. Managing partner of the New York office and leader of the firm’s prosecution and transactions group MacLeod is the recipient of exuberant praise: “Janet has a knack for getting to the heart of a complicated biotech invention and drafting broad, enforceable and commercially relevant claims. She dispenses candid and pragmatic advice and is a trusted adviser who helps you achieve your most critical IP and business goals. Every member of her team follows her lead and is amazingly responsive.” The Mount Sinai School of Medicine, Rutgers University and the Ludwig Institute for Cancer Research are just some of the eminent clients she supports. With more than 30 years of experience, Somerville is a percipient counsellor. One of her recent projects involved guiding MeiraGTx with respect to IP due diligence in the run up to the successful closing of its initial public offering in June 2018.

Gibson Dunn & Crutcher LLP

“Through the use of analytics, general counsels are seeing what gets them success with greater clarity and, as a result, increasingly turning to firms like Gibson Dunn.” Its elite cadre of trial lawyers have gone the distance and won many times, which not only inspires confidence during the most fractious of disputes but creates immense threat value that can be capitalised on to facilitate quick wins in many circumstances. The prestigious firm has six New Yorkers in the IAM Patent 1000 this year, up from four the previous year and the newcomers are life sciences mavens Jane Love and Robert Trenchard. Their recent work for Novartis has been turning heads; in an inter partes review filed by Apotex challenging the patent on the dosing regiment for Novartis’s blockbuster drug Gilenya, the PTAB rejected all grounds of alleged invalidity after a full trial on the merits – an outcome that saw Novartis’s stock price increase by billions. With her well-rounded patent practice, philosophy doctor Love is most-suited to post-grant work, while Trenchard is a veteran persuader with wide-ranging litigation experience. The ranked returnees are Josh Krevitt, Daniel Thomasch, Benjamin Hershkowitz, and Brian Rosenthal, all of whom are poised advocates and repositories of trust for prestigious companies. Krevitt and Thomasch were called on by T-Mobile just four months before trial to take over the defence of multiple cases from another top IP firm in which Huawei is threatening to shut down T-Mobile’s entire 4G LTE network. Hershkowitz has been working with Krevitt on another telecoms dispute, acting for AT&T and other wireless carriers in a case filed by the Regents of the University of Minnesota – again in this case, billions are at stake. Staying in the same industry, Rosenthal secured judgment on the pleadings for Gemalto M2M and nine other defendants in an action brought by Dutch entity KPN asserting a telecoms error-checking patent deemed to be standard essential.

Goodwin Procter LLP

Goodwin Procter sets the standard for the advancement of industry practice in the life sciences and has many star patent litigators among its ranks. This includes veterans such as firm chairman David Hashmall and generic pharmaceutical doyenne Elizabeth Holland, but also next-generation leaders such as Robert Cerwinski and Huiya Wu, both of whom come in for vociferous recommendations from clients: “Rob is a top expert when it comes to patent litigation, strategic IP counselling, due diligence and inter partes reviews and provides exceptional guidance on commercially significant matters. His in-depth scientific knowledge and deep understanding of FDA regulatory matters are a major asset for drug development and patent challenges. He appreciates the demands on global corporations and is excellent when conducting risk analysis across multiple jurisdictions. He is someone you can count on to bring about the best results in the most efficient manner.” “Huiya is a pharmaceutical client’s dream – a stellar and versatile IP litigator with vast experience in Hatch-Waxman Act and biosimilar cases and post-grant proceedings and a profound understanding of the business underlying the drug industry. She has fantastic judgement and an innate ability to think on her feet in exceptionally strategic and creative ways.” The pair recently joined forces to earn a PTAB victory for Celltrion against Genentech, which helps Celltrion as it readies a biosimilar to Genentech’s Herceptin product. In Mark Abate and Ira Levy, Goodwin also has champions for non-life sciences companies. Abate has long represented IBM and pushed at the boundaries of patent law in a number of cases; Levy has litigated in many industries and technologies and has never been found wanting in terms of technical or advocacy skill.

Greenberg Traurig LLP

Every action that Greenberg Traurig takes in the patent space is guided by the business concerns and objectives of its clients – this is the secret to the success of its many long-term relationships with top innovators. Setting the tone in this regard is GT patent lawyer number one Scott Bornstein, who co-chairs the global IP and technology practice. He is an eminently experienced trial lawyer – the number of times he has taken the lead on patent litigations reaches into the triple digits – but is so much more than that; his clients treat him as a trusted adviser due to his broad horizons and strategic perspicacity. He and local IP chair Joshua Raskin are inspirational leaders for a hearty crew in the Big Apple that includes cultured litigators Allan Kassenoff, Jonathan Ball and Richard Pettus. Exceptionally well integrated as a team, they all work in harmony for Teva and B Braun Melsungen in multiple district court litigations and PTAB actions.

Haley Guiliano LLP 

Haley Guiliano was founded by the partners in charge of Ropes & Gray’s IP rights management practice and opened for business in August 2017. Scoring high marks for its commercial approach to patent protection and portfolio development, it now makes its debut in the IAM Patent 1000. James Haley takes the lead on the dynamic set’s life sciences activities – he prosecutes for AbbVie, oversees global filing for Agene Bio and serves as lead counsel in inter partes reviews for other market leaders. “Jim has been representing the biotech industry from basically the beginning of its existence. His breadth and depth of experience is unparalleled and he has profound knowledge about what can be patented not only in the United Sates but also by the EPO and other leading patent offices in the world.” Renowned as a fabulous life sciences strategist globally, he was responsible for creating the hybridisation language for nucleic acid sequence claims and the encoded proteins – before mass sequencing became available this had a significant impact on international patenting policy. Putting quality first on the high-tech side of the practice is Joseph Guiliano.

Haug Partners LLP

“Haug Partners is an example of a firm that has thrived and progressively expanded its market share through a challenging half decade. The firm performs brilliantly in litigation particularly in the pharmaceutical sector and has a team talisman in Edgar Haug. Ed is an excellent trial lawyer – he takes a no-nonsense approach and gets right to the point in his advocacy; he has also been around the block and is hugely respected by judges.” Add in Porter Fleming and Angus Chen and Haug have got something special going on. Astute in leveraging the right talent within the firm for each case, Fleming has been leading the litigation group to win after win. While Chen is highly valued for his technical dexterity and is also a “thoughtful practitioner with a nice, understated but very persuasive presentation style”.

Hughes Hubbard & Reed LLP

Despite its compact size, Hughes Hubbard’s patent litigation group has had a tremendous influence on the direction of US patent law. For example, chair of the practice James Dabney served as lead counsel for the petitioner in KSR International v Teleflex, a 2007 Supreme Court case that overturned decades of legal precedent regarding non-obvious subject matter under Title 35 of the US Code, Section 103; and in 2017, he acted for TC Heartland against Kraft Food Group in a case that changed the law on patent venue. Dabney is a student of history and a pioneer who solves complex problems with alacrity while delivering commercial advice. More recently he has been working miracles for Automated Packaging Systems, securing a dismissal with prejudice of an action brought by competitor Free-Flow Packaging International; for Costco Wholesale in winning summary judgment, dismissing patent infringement claims made by Robert Bosch, alongside multiple inter partes review victories; and for L&R USA in obtaining a permanent injunction order against Crawford Healthcare. He frequently teams up with Patrice Jean, a firecracker of a litigator who takes no nonsense from even the most aggressive opponents. She gets up to speed on new and complex matters with frightening velocity and is happy being thrown in at the deep end when required.

Hunton Andrews Kurth LLP

The upheaval of a major merger – the April 2018 combination of Andrews Kurth Kenyon and Hunton & Williams – has not affected the flow of John Flock, Michael Lennon and Clifford Ulrich in New York; they have all stayed close to long-term clients by delivering crisp results in patent suits and post-grant proceedings. Flock, who has taken on the mantle of IP group co-leader, remains a go-to guy for Sony and recently represented the electronics leader in an ITC litigation, successfully arguing as to the invalidity for indefiniteness of the asserted patents. He has a comprehensive knowledge of Sony’s innovation philosophy and commercial objectives, which he translates into wins on a consistent basis – something which holds true for many of his patrons. Lennon continues to serve Volkswagen Group of America and, with Ulrich, lately won a slew of inter partes reviews for the automotive giant. Lennon’s blend of litigation and licensing expertise makes him a vital business partner for his clients; Ulrich is the set’s top post-issuance guru and a veteran on the challenger and patent owner sides.

Jones Day

As a life sciences firm, Jones Day is incredibly well rounded with patent procurement experts like Adriane Antler and sharpshooting litigators such as Pablo Hendler, John Normile and Christopher Harnett in the fold. To sweeten the deal, the side also has the backing of an excellent FDA regulatory and compliance counselling division. Co-leader of the global prosecution practice Antler is “extremely bright and has been doing cutting-edge biotech and pharmaceutical work for decades”; her experience makes her hotly sought after for patentability, infringement and validity opinions and commercial IP advice. Further, as a post-issuance practitioner she is distinguished by her knowledge of both US and European systems. Considered to be an equal by inventors and a like-minded commercial guy by business executives, Hendler has many admirers; lately he has successfully resolved several Hatch-Waxman Act and PTAB matters for Purdue Pharma alongside Normile, a katana-sharp strategist with 30 years of experience representing pharmaceutical originators. Representing Celgene at the PTAB has been a significant part of Harnett’s recent practice.

King & Spalding LLP

Ascendant national patent litigation firm King & Spalding made headlines in New York in summer 2018 when it recruited life sciences litigators Gerald Flattmann, Evan Diamond and Vanessa Yen from Paul Hastings. This has proven to be some inspired recruitment: “These three demonstrate amazing attention to detail – there is no aspect of their cases they do not know or appreciate – while maintaining clear strategic vision in a way that makes them unique. From pleadings to discovery to hearings and through closing arguments at trial, they perform flawlessly and obtain great results with the needs of their clients’ in-house counsel, internal stakeholders, witnesses and business associates in mind. They are not typical New Yorkers in the sense that they have tremendous soft skills and develop meaningful relationships with everyone they meet. If you have these fine lawyers representing you, then consider yourself privileged.” Of course, King & Spalding already had a fine pharmaceutical and biotech practice on the non-contentious side anchored by long-tenured partners and patent polymaths Kenneth Sonnenfeld and Margaret Brivanlou. Both industry insiders, they help clients to carve out strong market positions by making all the right moves in prosecution and licensing.

Kirkland & Ellis LLP 

For tour de force patent litigation performances, Kirkland & Ellis will not let you down; the firm is in its element when competitors are battling over game-changing life sciences and technology innovations and with billions of dollars on the line. In “aggressive but fair fighter” Leora Ben-Ami, the firm has “one of the top five biotech patent practitioners in the country”. Patricia Carson is also highly respected in the life sciences milieu; those in the know report that she has been linking up to great effect with Jim Hurst out of Kirkland’s Chicago office. Over on the high-tech side, Gregory Arovas understands the finer points of litigation strategy and personifies the firm’s tactical ingenuity; he is a “heavy hitter” in district court cases and at the ITC. Robert Appleby is a master of the electrical arts too; the broad-minded lawyer deploys to great effect on convoluted cases with patent, design, trade secret and unfair competition elements. Kirkland & Ellis also maintains one of the longest-established patent licensing practices in the country and has a well-integrated coast-to-coast team of specialised experts in the discipline. David MacDonald, the top transactions lawyer in New York, links up well with his litigation colleagues and brings nuanced negotiation skills to settlement talks for clients such as Abbott Laboratories, Teva and Samsung. A lot of his work is standalone, for example advising Open Innovation Network on patent strategy and pool licensing for Linux systems and acting for Tigen Pharma on a collaboration with the Ludwig Institute for Cancer Research.

Leason Ellis LLP

Harnessing deep technical expertise and excellent business judgement, Leason Ellis takes inspiration from founding and managing partner David Leason in the provision of world-class prosecution and counselling services. One of the jewels in its crown is the life sciences practice captained by Elizabeth Barnhard, an astute risk manager and global patent strategist with decades of experience in the pharmaceutical industry. By her side is Susie Cheng who adds tremendous value as a “great idea generator”. “In difficult and emerging areas of intellectual property, she comes up with novel and interesting ways to manage IP assets. Knowledgeable and resourceful, she is one of the most dependable lawyers in the life sciences.” With his outstanding record of scholastic achievement and in-house experience in a multinational pharmaceutical company, Michael Davitz brings both academic rigour and commerciality to the table. He is highly versatile too: prosecuting pharmaceutical, biotech, medical device and IT patents; guiding clients on licensing matters; and advising on Hatch-Waxman Act litigation strategy are all things he does at the highest level. “Quick thinking, clear and thorough, Michael moves complex matters on at a fast clip. He also has a strong desire to make the world a better place and for that deserves the highest commendation.” Growth in litigation is one of Leason Ellis’s priorities and helping bring it about is Melvin Garner, an experienced lead counsel whose well-rounded prosecution, licensing and litigation abilities are ideal for resolving challenging disputes. The firm made a smart move in February 2018 bringing ex-Orrick partner Robert Isackson on board: “He’s a creative trial lawyer who thinks outside the box and has an excellent understanding of the technology at issue in his cases and the business concerns of his clients. He’s up front about the chances of success, the time commitment of particular courses of action and associated costs and makes getting to a desired outcome a team effort with his clients.”

Mayer Brown

Pharmaceutical and biotech litigation filings remain healthy but, as fewer cases are going to trial, competition has increased between major law firms in the sector; Mayer Brown, with its long-established and close relationships with top life sciences innovators, remains one of the leading players. Its excellent track record makes a huge difference – something which New York lawyers Lisa Ferri, Brian Nolan and Richard McCormick are responsible for; recently they have been out to bat for Sanofi and won summary judgment of non-infringement in a cancer medication case against the Washington Research Foundation and Genentech. Ferri had a big year in 2018 when she became co-chair of Mayer Brown’s global IP practice; as a “fantastic lawyer and great leader”, she is well suited to the role. She and Nolan “develop excellent strategies that inspire huge victories in trial and appellate courts” as a matter of routine and are “extremely hardworking and thoughtful lawyers”. Making a vital contribution with his litigation skill and technical expertise, McCormick joins them in the IAM Patent 1000 for the first time this year. Together with Ferri, he is currently representing Bristol-Myers Squibb, Ono Pharmaceutical and Tasuko Honjo in a patent infringement case against EMD Serono, Merck and Pfizer in the cancer immunotherapy area.

Milbank LLP

Plenty of firms handle a greater volume of patent cases but not many get to trial as often as Milbank – and even fewer have an equally outstanding record. Milbank’s lawyers are among the most battle-hardened in the market and showcase finely calibrated courtroom skills; for a great example check out “superb pharmaceutical litigation strategist” and “lethal cross examiner” Errol Taylor. Alongside Fredrick Zullow Taylor leads a dynamic life sciences team that recently secured a huge Federal Circuit victory for Orexo in a patent infringement suit against Actavis, as a result of which Orexo’s flagship Zubsolv opioid addiction treatment product has protection through to patent expiration in 2032. In the electrical, semiconductor, computer, fintech and medical device theatres, Christopher Gaspar is the best bet for a win. “He is a phenomenal lawyer who thinks three steps ahead of everyone else and has all the bases covered.” He and Los Angeles-based Mark Scarsi form one of the top litigation pairings in the entire country and bring the heat for many pre-eminent technology companies.

Norton Rose Fulbright US LLP

Norton Rose Fulbright’s US patent activities are impressive in scale and scope; the firm manages the portfolios of some of the most prolific US patent filers; undertakes important litigation challenges; and demonstrates post-grant thought leadership through its Patent Challenges blog (which is translated into Japanese). Moreover, with more than 300 IP professionals in 20 offices on five continents Norton Rose Fulbright puts a well-integrated global IP practice at the disposal of its patrons. Placing the set’s New York practice under the microscope reveals an excellent pharmaceutical and biotechnology litigation offering at the forefront of which is Jeffrey Lewis. A chemical engineer, registered patent attorney and top trial lawyer, Lewis is a rare breed. He dexterously handles the largest of Abbreviated New Drug Application cases, his representation of Purdue Pharma in a suit asserting 35 patents in nine consolidated litigations against Alvogen and Actavis – who sought to launch a generic version of Purdue’s Hysingla ER product – being a particularly striking example. Paul Keller takes care of pharmaceutical matters too, but is a rangy lawyer who works across multiple industries with confidence and poise. In a bet-the-company case with broader content-streaming industry ramifications, he is acting for Touchstream Technologies (doing business as Shodogg) against Vizbee.

O’Melveny & Myers LLP

Protecting AstraZeneca’s critical Faslodex breast cancer treatment in Hatch-Waxman Act litigation against multiple waves of generic companies; filing lawsuits for Onyx Therapeutics against 11 generics seeking FDA approval to market generic versions of cancer drug Kyprolis; and undertaking extensive biosimilar litigation work for two global pharmaceutical companies, O’Melveny has been going great guns in the life sciences lately. Leading from the vanguard is the “amazing” Lisa Pensabene, “a total master of pharmaceutical patent litigation”. “Creative and courageous, Lisa is not afraid to try strategies outside of the traditional playbook. She is dynamic and skilled in the courtroom and a leader who excels at developing the young supporting talent around her. She is also extremely energetic and a lot of fun to work with.” The diversity of her team, which includes more women than men, is pleasing to see and something that judges acknowledge favourably; it is also a young team and is therefore well prepared for the future.

Patterson Belknap Webb & Tyler LLP

Prestigious, lean, single-office New York firm Patterson Belknap is “a major player on the branded side of the pharmaceutical industry” although its many “outstanding trial lawyers” are proficient in all forms of patent litigation. William Cavanaugh, Gregory Diskant and Lewis Popovski form one of the most experienced triumvirates in the IAM Patent 1000. Over the decades, each lawyer has fought and won many consequential lawsuits, which has resulted in billions of dollars being awarded to their clients.

Paul Hastings LLP

Brilliant at trial, triumphant before the PTAB and accomplished at the appellate level, Paul Hastings has one of the most mature and sophisticated patent litigation practices in the United States. Look across its group in New York and it is apparent that, despite the loss of an experienced trio of lawyers to King & Spalding, the firm remains in excellent order. Pharmaceutical supremoes Bruce Wexler and Eric Dittmann have been performing at a championship level for Boehringer Ingelheim, successfully taking it through two inter partes reviews resulting in the invalidation of all claims of a key patent covering the most widely used indication for AbbVie’s Humira drug and securing a comprehensive victory for the company in a multi-defendant litigation concerning its blockbuster drug-thinner product Pradaxa. Wexler chairs the life sciences practice and is admired for his aggressive yet refined approach. Dittmann serves as global IP vice chair alongside Joseph O’Malley, who is lauded as “one of the pharmaceutical industry’s most authoritative voices”; together they recently won a major trial victory for Helsinn Healthcare against Teva Pharmaceuticals, which was found to have infringed Helsinn’s flagship Aloxi drug – a case of first impression concerning the issue of whether an alleged sale must make the claimed invention available to the public to trigger the America Invents Act on sale bar. New to the guide this year, former Patterson Belknap trial lawyer Chad Peterman is hailed as a “hardworking, collegial lawyer who focuses 100% on his clients’ best commercial interests”. Alongside Wexler, he achieved a stomping win for Orexigen Therapeutics in a hard-fought litigation against Teva; this was to protect Contrave, Orexigen’s only product, which proves that companies seek out Paul Hastings when literally everything is on the line. Preston Ratliff II also carries the day for drug companies and has lately successfully represented Sumitomo Dainippon Pharma and subsidiary Sunovian in a hotly contentious dispute over Latuda, the client’s billion-dollar schizophrenia drug. For many of the set’s life sciences clients – and for the wider firm’s high-tech patrons – transactional lawyer Samuel Waxman is a vital resource. He has represented Deerfield Management in multiple life sciences research partnership deals.

Paul, Weiss, Rifkind, Wharton & Garrison LLP

Ascending to the New York patent litigation gold tier this year, Paul, Weiss is “at the top of its game” while many of its competitors are getting long in the tooth. “Aggressive, tough and smart” in high-risk, high-impact mandates, its consummate trial lawyers operate at the cutting edge of developments in the life sciences, medical equipment, healthcare and technology sectors. There are many pertinent examples of this – from representing Amgen in biosimilar litigation, to acting for Edwards Lifesciences against Boston Scientific in a major battle in the transcatheter heart-valve space. Teaming up in various combinations to deliver the goods are Nicholas Groombridge and rising stars Eric Stone, Jennifer Wu and Catherine Nyarady – all “extremely persuasive” litigators who maintain perfect balance in fast-moving and complex district court and PTAB cases filled with traps for the unwary.

Perkins Coie LLP 

In recent years, Perkins Coie has emerged as a national destination firm for patent litigation, its performance history in all fora has proven to be simply irresistible to corporate counsel when the stakes are high. William McCabe is the lawyer who has put the firm on the map in New York. “He considers the full arsenal of available weapons and works out the most effective overall case strategies. He represents his clients very aggressively but is never anything less than a fair opponent.” Fellow high-technologist Gene Lee is another experienced lead counsel and a major contributor to the firm’s post-grant practice.

Proskauer Rose LLP

Potent in litigation, meticulous in prosecution and ultra-commercial in transactions, Proskauer Rose stands sentinel for leading innovators from businesses of all stripes. Its squad in New York shows off the firm’s many unique offerings, including a top-drawer patent pool evaluation, formation and operation capability and excellent life sciences and technology transactions practice. Patent pools are the domain of Kenneth Rubenstein, who is acclaimed as “one among a handful of the world’s leading patent practitioners. With his PhD in plasma physics from the Massachusetts Institute of Technology, Ken has a level of technical knowledge that the most sophisticated of engineers admire. What’s more, he can communicate the most complex of concepts in the simplest of words to be understood by the greatest number of people, experts or laymen. When it comes to SEP matters and pools, everyone tries to imitate him, but nobody can duplicate him – he’s a true pioneer.” Transactional work is the metier of Daryn Grossman, who co-chairs Proskauer’s global corporate department. In demand for her industry knowledge and decisive negotiation skills, she has recently handled an acquisition and research collaboration for pharmaceutical and chemical manufacturer Grifols, along with a notes offering, and confected a long-term strategic alliance between her client Celgene and Nimbus Therapeutics. Meanwhile, Baldassare Vinti and James Shalek are the lynchpins of the Proskauer litigation practice. At the outset of a case, Vinti focuses on establishing clear trial themes and targets the discovery effort on gathering the evidence that will be needed at trial – it is an approach that seems simple and logical, but it is not how a lot of patent litigation is done. He does not engage in wasteful action, which keeps costs down, and he helps clients to analyse the data they gather to ensure that commercial value is derived from every penny of their legal spend. Head of the patent group Shalek is also forward-thinking about litigation and trial team efficiency.

Quinn Emanuel Urquhart & Sullivan LLP

“If a case is going south and you’re not happy with existing counsel, Quinn Emanuel is the firm to turn things around – its lawyers get up to speed on complex cases rapidly and are guaranteed to do a sterling job at trial.” In New York, the gilt-edged firm has a lot of manpower, but also a lot of guile, with nine gifted advocates recommended in the IAM Patent 1000, more than any other firm in the city. Leading lights of the life sciences practice include Peter Armenio, Sandra Bresnick, Dominic Cerrito, Raymond Nimrod and Colleen Tracy James. “Peter is extremely quick on his feet and a cordial lawyer who works with, rather than purely against, opposing counsel in a way which is ultimately good for his clients.” He co-chairs the global life sciences group with Bresnick, whose combination of patent and product liability litigation expertise makes her an absolute asset. Of Cerrito, one source comments: “If I were a CEO with a bet-the-farm case, I’d hire him. He’s intimidatingly aggressive and incredibly effective.” Nimrod is noted by the market for his representation of Merck Sharp & Dohme in many of its toughest cases. Tracy James is a recent arrival at Quinn having transferred over from Mayer Brown in November 2018. “Colleen has fantastic litigation skills and judgement and does a brilliant job when coming up against top adversaries. She is tremendous to work with and makes the job of in-house counsel so much easier.” Making up an equally proficient strike team on the high-tech side are Edward DeFranco and Thomas Pease. DeFranco co-chairs the national IP litigation practice and provides gold-standard representation in district courts and at the ITC to a host of blue-chip patrons. Pease is Quinn’s SEP guru. Backing them all up at the Federal Circuit is Kathleen Sullivan, one of the principal appellate lawyers in the country in any discipline.

Robins Kaplan LLP

Robins Kaplan scored a coup in October 2018 when it landed former Orrick partner Elizabeth Gardner. With her decades of courtroom experience and broad technical compass she will fit right in at her now home, which is renowned for its superlative advocacy and deft trial handling. Chiefly responsible for conferring this reputation on the ensemble is New York managing partner Ronald Schutz, he is an American College of Trial Lawyers fellow and a world-class IP value-creator who is also recommended in the IAM Strategy 300.

Ropes & Gray LLP

Ropes & Gray’s patent practice has been designed to meet the needs of a high-level client base for whom intellectual property is pivotal; best known for its decisive execution in district courts, at the PTAB and the ITC, the firm is a redoubtable litigation force but also shines when it comes to international transactions and strategic counselling. A notable recent development for the outfit is the evolution of its life sciences practice starting with and following the February 2018 recruitment of O’Melveny partner Filko Prugo. His two decades of experience on the frontlines of Hatch-Waxman Act litigations and, more recently of disputes under the Biologics Price Competition and Innovation Act, certainly make an excellent platform on which to build. Meanwhile, keeping Ropes at the forefront of heavily contested matters in the semiconductor, computer technology, telecoms and consumer electronics fields is Steven Pepe. Linking up with several partners in California, including Andrew Thomases, Pepe has lately been representing Godo Kaisha IP Bridge 1 in suits against TCL Communication Technology, Intel and Qualcomm. Remaining hugely influential in the technology litigation practice is Jesse Jenner, a senior counsel who “understands the big picture”. One former adversary describes her as “hands down the best lawyer I’ve ever seen in court”.

Shearman & Sterling LLP 

Those watching the automotive, software and semiconductor sectors will have seen the rigour with which Shearman & Sterling approach every litigation engagement. Recently Mark Hannemann and Thomas Makin have been putting in robust performances for Robert Bosch against Costco, which has made many attempts to have Bosch’s windshield wiper patents revoked and asserting five patents in a multi-faceted patent, copyright, trade secret and unfair competition case for pricing software company Pricef(x). As a first-chair trial lawyer, Hannemann has gone the distance and won on multiple occasions – it is his experience that leads people to seek him out. Working from an exceptionally strong technical foundation, Makin is a detail-oriented lawyer who gets things done right the first time for his ardent following of Japanese companies. The practice in New York has been satisfyingly stable and consistent of late; whereas out west there have been major developments – new arrivals in San Francisco and Menlo Park have bolstered the firm’s litigation and transactional practices. Speaking of the latter, Jordan Altman debuts in the IAM Patent 1000 this year. Coming from a prosecution background – he is a former USPTO examiner – and being experienced in patent and trade secret litigation, he is well equipped to safeguard the passage of IP rights between the parties to a complex deal.

Skadden Arps Slate Meagher & Flom LLP

In the IP and technology transactions space there are only a handful of firms that can even come close to Skadden in terms of resources, depth, quality and credentials. Among its “commercial superstars” are Bruce Goldner, a connoisseur of brands and patents; Stuart Levi, a thought and practice leader in outsourcing, privacy law, fintech and blockchain matters; Stanford University organic chemistry PhD Matthew Zisk and “tireless around-the-clock worker” Resa Schlossberg, who are both life sciences maestros; and Jose Esteves, a celebrated IP value creator whose niche lies where sophisticated legal, business and technical issues converge. The strategic creativity they all bring to deals is mirrored in the way in which Anthony Sammi and Douglas Nemec tackle patent litigation. Unsurprisingly given their environment, the pair are especially impressive on licensing and breach of contract disputes. Close integration between the transactional and litigation practices and the New York and Silicon Valley teams ensures a joined-up approach to the most challenging IP and technology head scratchers.

Steptoe & Johnson LLP

As the home to litigators John Molenda and Vishal Gupta and strategic prosecution and portfolio management guru Ying Li, New York is the nerve centre of Steptoe’s first-rate healthcare and life sciences industry practice. Armed with a chemistry PhD, Molenda is one of the most technically deft members of the patent trial bar – no wonder, then, that he has enjoyed much success at the PTAB. On top of his extensive experience in district courts countrywide, he knows the lay of the land at the Federal Circuit too, which makes him a truly accomplished litigator. His appellate expertise was particularly useful during his representation of Sanofi and Regeneron in defence of high-cholesterol antibody therapy Praluent; having lost on the sole issue of validity following a jury trial, Molenda appealed to the Federal Circuit, which remanded the case for a new trial. With him on this was fellow scientist Gupta, who before entering the legal profession formulated pharmaceuticals and conducted research at Massachusetts General Hospital and Harvard Medical School. Li, who earned her immunology PhD from Harvard, enters the IAM Patent 1000 rankings this year following ardent acclaim from the market: “Ying’s scientific understanding is amazing but she also has a great ability to be practical. She’s a top prosecutor who also knows what needs to go into an IP contract.” She has a global following and counsels Sanofi in several key therapeutic areas, emerging Danish biotech star Symphogen and Chinese start-up Zhejiang DTRM Biopharma.

Sullivan & Cromwell LLP 

In litigation and deal work Sullivan & Cromwell is accustomed to breaking new legal ground while shaping entire technology sectors. Its lawyers have all the technical legal skills that could ever be required and are also deep commercial thinkers who never fail to appreciate the big picture. On the contentious side, Garrard R Beeney “stakes out positions that are extremely well thought out by utilising his exceptional advocacy skills. He understands what is and isn’t important and is a collegial attorney who never makes life harder than it needs to be.” His recent work includes winning an $814.9 million award for BlackBerry in a binding arbitration against Qualcomm – one of the biggest commercial arbitration awards on record; add to this interest and attorneys’ fees and the total came to $940 million. Deploying his world-class licensing and SEP expertise, he also successfully represented Audio MPEG, US Philips Corporation, TDF SAS and IRT as MP3 patent owners against HP and Dell. Partnering regularly with celebrated commercial IP lawyer Nader Mousavi in Palo Alto, Mehdi Ansari is a rising technology transactions star. He has been representing Amazon and recently handled its $13.7 billion acquisition of Whole Foods Market – a good example of the landscaping referred to earlier. As a top M&A and cybersecurity partner at one of the world’s most illustrious law firms, John Evangelakos brings gravitas to the negotiation table.

Venable LLP

The addition of Fitzpatrick’s lawyers in August 2018 has supercharged Venable’s IP line-up and given the firm a massive 160-plus lawyer presence in New York. More specifically, Venable can lay claim to a top litigation and transactional life sciences practice now that Dominick Conde, William Solander, Scott Reed, John Murnane and Alicia Russo have been brought into the fold. IP division co-chair Conde comes in for considerable commendation from industry leaders: “Too many litigators substitute mindless aggression for sound judgement; Dom is tenacious but has a nuanced understanding of how a case will play out and gives pragmatic and strategic advice. He also doesn’t stop thinking about his clients once a case is over – he’ll proactively get in contact about relevant developments in intellectual property that might have an impact on your business strategy and does a lot of sophisticated non-traditional counselling work that you’ll never read about.” Solander has a compelling command of international IP law and is an absolute ace when it comes to cross-border litigations. Reed advocates primarily in the life sciences domain but is highly proficient in the electrical arts too. Murnane is a seasoned originator-versus-generic battler who knows his way around all major patent litigation forums in the United States. Russo co-chairs the IP transactions group and focuses on biologics and small molecule pharmaceuticals. “Dedicated and precise, she provides valuable guidance and handles matters promptly and excellently. As a patent prosecutor and freedom-to-operate opinion giver, she has an excellent batting average.” The former head of Fitzpatrick’s electronic and computer technologies group Michael Sandonato has also hit the ground running at Venable and co-leads the firm’s IP litigation group. He has represented Canon as lead trial lawyer for many years. Serving as IP head in New York, eight-year Venable veteran Frank Gasparo now has lots of new partners to brainstorm with. He litigates across the IP spectrum and is a “top-level strategist who sees the whole playing field”.

Weil Gotshal & Manges LLP 

“Weil’s technology and IP transactions specialists are great at issue spotting and problem solving. Having done a massive amount of deal work, they don’t get bogged down no matter how complex things are and drive excellent outcomes in a highly pragmatic fashion.” Setting the tone in this regard is captain of the side Michael Epstein, a total master of the IP aspects of major M&As who is also emerging as an authority on intellectual property in bankruptcy contexts. Frequent collaborators Charan Sandhu and Jeffrey Osterman are further top-level negotiators. As one client espouses: “With some lawyers, you end up spending a lot of time (and therefore money) explaining what your technology is and what you’re trying to achieve but Charan and Jeffrey understand these things immediately; they then add value by suggesting things you could be doing but might not have thought about. Utterly dedicated to their projects, they are efficient lawyers who help maximise the value of your intellectual property and technology.” To touch on some deal highlights, Epstein acted for Campbell Soup Company in connection with its $6.1 billion acquisition of Snyder’s-Lance, while Sandhu and Osterman advised General Electric on its $2.6 billion sale of GE Industrial Solutions to Swiss company ABB. Pharmaceutical doyenne Elizabeth Stotland Weiswasser is a pillar of Weil’s potent national patent litigation practice. She and Anish Desai have been the driving forces behind the firm’s life sciences practice and have, for example, been asserting patents directed to Sanofi’s multi-billion-dollar Lantus SoloSTAR insulin biologic against Mylan recently. Demonstrating excellent tactical foresight, both are brilliantly smart, technically fluent and fantastic on their feet.

White & Case LLP

White & Case’s litigators are smooth operators on behalf of technology and life sciences industry leaders – nothing throws them off their trial game. Gold-rated Dimitrios Drivas has been ramping it up in the biosimilar litigation area acting for Pfizer among others; he knows the Biologics Price Competition and Innovation Act back to front and has decades of experience at the pinnacle of the drug industry. Matters sitting at the intersection of IP and antitrust law are meat and drink for Raj Gandesha, which makes him a particularly valuable ally to the firm’s pharmaceutical clients. In the medical technology space, Scott Weingaertner is the first choice of cardiovascular pioneers such as Abiomed and Biotronik. He has been teaming up to great effect with well-connected colleagues in Boston such as Charles Larsen. White & Case has been crazy busy on the M&A and tech transactions front lately; the sheer volume of work that specialists Arlene Hahn and Adam Chernichaw undertake means that they have the most nuanced understanding of what is commercially reasonable in the eyes of the market; knowing the tech is just as valuable of course, and these guys have it on lock.

Wilmer Cutler Pickering Hale and Dorr LLP

Effective collaboration across multiple offices is one of the keys to WilmerHale’s awesome success in patent litigation; when star lawyers like Palo Alto partner Mark Selwyn and Boston’s Bill Lee join forces, there is nothing that can stop them getting to where they want to go. Look closely at the New York office and you will see an exceptionally talented bunch with an especially vibrant life sciences practice. First to mind are Robert Gunther, a “super creative and accomplished lawyer” and David Bassett, an “excellent writer and top-notch courtroom advocate”. Gunther has consistently been on the money when representing Genentech and Roche Molecular Systems in multiple cases; the same applies for Bassett with his major clients, including Gilead Sciences.

Winston & Strawn LLP 

Winston & Strawn is famed around the world for its patent trial finesse, but less well known for its prosecution proficiency. However, in New York it has one of the best counsellors in the city and indeed the whole country: “Pejman Sharifi is extremely creative and efficient at procuring patents – he rolls up his sleeves and gets things done.” He has recently taken over leadership of the non-contentious practice following the retirement of Allan Fanucci. Back to litigation, Michael Murray and Krishnan Padmanabhan form the local A-team. Murray makes regular appearances at the ITC and the PTAB and is an opinion maker on subjects such as patent eligibility. A rising star who debuts in the IAM Patent 1000 for 2019, Padmanabhan is taking the telecoms industry by storm. He understands the business objectives of leading cable companies and knows how to realise them through effective litigation.

Other recommended experts

Acting on behalf of Bayer against Baxalta, Sidley recently emerged victorious from a jury trial with an award of $155 million. The mastermind behind this victory was Jim Badke, who leads the firm’s robust IP litigation practice. Jennifer Coplan is another well-known Sidley name and co-chairs the technology and IP transactions practice. Karen Bromberg and Francisco Villegas wear the Cohen & Gresser crest. Efficient at facilitating early wins but always prepared to go the distance, these litigators have an excellent track record in district court actions and PTAB proceedings. Successfully enforcing FirePASS’s patent portfolio against Boeing and Honeywell is one of their recent major accomplishments. Everyone thinks highly of Latham’s litigators and New York sources identify Daniel Brown as one of the firm’s best pharmaceutical lawyers. Alongside running an impressive life sciences litigation practice out of Chicago, Schiff Hardin completes quality prosecution work with New York’s Laura Brutman taking the lead. Acting for powerful IT and semiconductor entities, she puts quality first. At Orrick, seasoned trial lawyer Joseph Calvaruso and Supreme Court and appellate practice leader Joshua Rosenkranz are individuals that clients want by their side when they are heading into battle. Garnering particular praise this year, Rosenkranz has “an abyssal depth of legal knowledge which he tempers well with a very practical approach. He puts in an incredible amount of preparation work so that, on the day, he can make everything look effortless.” Hogan Lovells life sciences litigator Arlene Chow has “great courtroom presence” and is a “zealous advocate for her clients but a collegial and fair lawyer”. Her colleague and fellow pharmaceutical and biotech expert Adam Golden leads the New York corporate group. Locke Lord IP chair Alan Clement deftly resolves complex multi-patent pharmaceutical disputes for the likes of Hikma. The veteran Hatch-Waxman Act litigator is also a confident patent prosecutor. Michael Dougherty and Tony Pezzano recently swapped Hogan Lovells for DLA Piper and are busy strengthening and building out their new firm’s Hatch-Waxman Act litigation practice. The two USPTO-registered attorneys are steeped in the pharmaceutical industry. Ivor Elrifi is Cooley’s man in New York and chair of the firmwide patent counselling and prosecution group. As a prosecuting, litigating and licensing biotech lawyer he is exceptionally well rounded. Buchanan Ingersoll & Rooney litigator Philip Hirschhorn resolves pharmaceutical and chemical cases in commercially optimal ways for his clients. Pryor Cashman partner Jeffrey Johnson is always getting his teeth into diverse and interesting work; the IP commercialisation ace acts for celebrities investing in technology and for emerging cannabis enterprises at the same time as representing more traditional corporations and private equity funds. “Lori Lesser is a fine transactions lawyer at Simpson Thacher & Bartlett. She knows IP law cold and is laser-focused on finding solutions and getting deals done.” Experienced biotech and pharmaceutical lawyer – and interference veteran – Karen Mangasarian gives Foley & Lardner a presence on the IAM Patent 1000 New York prosecution table. Willkie Farr & Gallagher has had an extraordinarily busy year in patent litigation; dynamo Thomas Meloro served as lead trial counsel for Pfizer against Genentech and City of Hope regarding a biosimilar version of Herceptin; led Array Biopharma and others to success in inter partes reviews; won a Federal Circuit appeal for Amneal Pharmaceuticals against Merck Sharp & Dohme; and litigated under the Hatch-Waxman Act numerous times. Co-founder of Lucas & Mercanti Michael Mercanti is an excellent choice as a global strategist for life sciences companies. He speaks the same technical language as inventors and knows how to relay information to the C-suite. Deepro Mukerjee has been having a whale of a time since he moved to Katten to co-chair its national patent litigation practice in 2018. As the preferred lead counsel for multiple leading drug manufacturers, Mukerjee is eminently practical and commercial and maintains a bottom-line focus throughout all phases of litigation. One of Wolf, Greenfield & Sacks’s top litigators, Michael Rader has impressed with recent victories for Sony at the ITC, PTAB and Federal Circuit and for Dell EMC in a District of Delaware trial. Since his time at Fish & Neave in the early 1990s, David Radulescu has worked in numerous prestigious firms, including Fried Frank, Weil and Quinn Emanuel. In the six years since he set up his own eponymous firm, the electrical engineering PhD has continued to perform at the highest level when grappling with convoluted high-tech patent litigations that go right to the heart of the business for the parties involved. Harry Rubin chairs the technology and IP transactions practice at Kramer Levin. The former Ropes lawyer is a global thinker when it comes to realising commercial value from patent assets. Brian Slater recently became head of the life sciences practice at Pierce Bainbridge. The experienced life sciences litigator is a former star of Fitzpatrick. Redoubtable litigation firm Susman is a repository of trust when much is at stake; its trial lawyers like Arun Subramanian consistently secure important and frequently against-the-odds wins on both sides of the docket. Subramanian knows the judges and the general lay of the land in hotspots like the District of Delaware and Eastern District of Texas. “Beyond his uncanny predictive accuracy, Charles Weiss has a superb ability to cut through the noise in litigation to keep everything and everyone on track toward the ultimate business goal. You can’t get better than him for representation in the most demanding, high-impact pharmaceutical litigations and transactions.” The hugely popular healthcare and life sciences whizz provides shrewd leadership to Holland & Knight’s New York IP group.

Individuals: litigation

  • Peter J Armenio PC - Quinn Emanuel Urquhart & Sullivan LLP
  • Gregory S Arovas - Kirkland & Ellis LLP
  • Garrard R Beeney - Sullivan & Cromwell LLP 
  • Evan R Chesler - Cravath, Swaine & Moore LLP 
  • Dominick Conde - Venable LLP
  • Edward J DeFranco - Quinn Emanuel Urquhart & Sullivan LLP
  • John M Desmarais - Desmarais LLP 
  • Dimitrios T Drivas - White & Case LLP
  • Gerald J Flattmann Jr - King & Spalding LLP
  • Nicholas Groombridge - Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • Edgar H Haug - Haug Partners LLP
  • Elizabeth J Holland - Goodwin Procter LLP
  • Keith R Hummel - Cravath, Swaine & Moore LLP 
  • Josh Krevitt - Gibson Dunn & Crutcher LLP
  • Joseph M O'Malley - Paul Hastings LLP
  • Kathleen M Sullivan - Quinn Emanuel Urquhart & Sullivan LLP
  • Errol B Taylor - Milbank LLP
  • Bruce M Wexler - Paul Hastings LLP
  • Mark J Abate - Goodwin Procter LLP
  • Robert A Appleby - Kirkland & Ellis LLP
  • Jim Badke - Sidley Austin LLP
  • David K Barr - Arnold & Porter Kaye Scholer LLP
  • David Bassett - Wilmer Cutler Pickering Hale and Dorr LLP
  • Leora Ben-Ami - Kirkland & Ellis LLP
  • Paul A Bondor - Desmarais LLP 
  • Scott J Bornstein - Greenberg Traurig LLP
  • Sandra A Bresnick - Quinn Emanuel Urquhart & Sullivan LLP
  • Daniel G Brown - Latham & Watkins LLP
  • Patricia Carson - Kirkland & Ellis LLP
  • William F Cavanaugh Jr - Patterson Belknap Webb & Tyler LLP
  • F Dominic Cerrito - Quinn Emanuel Urquhart & Sullivan LLP
  • Robert V Cerwinski - Goodwin Procter LLP
  • James W Dabney - Hughes Hubbard & Reed LLP
  • Daniel P DiNapoli - Arnold & Porter Kaye Scholer LLP
  • Gregory L Diskant - Patterson Belknap Webb & Tyler LLP
  • Lisa Ferri - Mayer Brown
  • Porter F Fleming - Haug Partners LLP
  • John Flock - Hunton Andrews Kurth LLP
  • Christopher J Gaspar - Milbank LLP
  • David Greenwald - Cravath, Swaine & Moore LLP 
  • Robert J Gunther - Wilmer Cutler Pickering Hale and Dorr LLP
  • David M Hashmall - Goodwin Procter LLP
  • Colleen Tracy James - Quinn Emanuel Urquhart & Sullivan LLP
  • Alan S Kellman - Desmarais LLP 
  • Michael J Lennon - Hunton Andrews Kurth LLP
  • Ira J Levy - Goodwin Procter LLP
  • Jeffrey ID Lewis - Norton Rose Fulbright US LLP
  • Robert Maier - Baker Botts LLP
  • David R Marriott - Cravath, Swaine & Moore LLP 
  • Jonas R McDavit - Desmarais LLP 
  • Kevin X McGann - Fenwick & West LLP
  • Thomas J Meloro - Willkie Farr & Gallagher LLP
  • Deepro R Mukerjee - Katten Muchin Rosenman LLP
  • Douglas R Nemec - Skadden Arps Slate Meagher & Flom LLP
  • Raymond N Nimrod - Quinn Emanuel Urquhart & Sullivan LLP
  • John Normile - Jones Day
  • Jeffrey Oelke - Fenwick & West LLP
  • Thomas Pease - Quinn Emanuel Urquhart & Sullivan LLP
  • Lisa B Pensabene - O’Melveny & Myers LLP
  • Chad Peterman - Paul Hastings LLP
  • Lewis V Popovski - Patterson Belknap Webb & Tyler LLP
  • Stephen S Rabinowitz - Dechert LLP
  • David C Radulescu - Radulescu LLP
  • Paul Ragusa - Baker Botts LLP
  • Scott K Reed - Venable LLP
  • E Joshua Rosenkranz - Orrick, Herrington & Sutcliffe LLP
  • Michael P Sandonato - Venable LLP
  • Robert C Scheinfeld - Baker Botts LLP
  • Ronald J Schutz - Robins Kaplan LLP
  • James Shalek - Proskauer Rose LLP
  • Neil Sirota - Baker Botts LLP
  • Brian V Slater - Pierce Bainbridge
  • William E Solander - Venable LLP
  • Richard J Stark - Cravath, Swaine & Moore LLP 
  • Aaron Stiefel - Arnold & Porter Kaye Scholer LLP
  • Daniel J Thomasch - Gibson Dunn & Crutcher LLP
  • Charles A Weiss - Holland & Knight LLP
  • Elizabeth Stotland Weiswasser - Weil Gotshal & Manges LLP
  • Huiya Wu - Goodwin Procter LLP
  • Fredrick M Zullow - Milbank LLP
  • James S Blank - Arnold & Porter Kaye Scholer LLP
  • Karen Bromberg - Cohen & Gresser LLP
  • Joseph A Calvaruso - Orrick, Herrington & Sutcliffe LLP
  • Angus Chen - Haug Partners LLP
  • Arlene L Chow - Hogan Lovells
  • Natalie C Clayton - Alston & Bird LLP
  • Alan Clement - Locke Lord LLP
  • Anish Desai - Weil Gotshal & Manges LLP
  • Evan Diamond - King & Spalding LLP
  • Eric W Dittmann - Paul Hastings LLP
  • Michael Dougherty - DLA Piper LLP (US)
  • Raj Gandesha - White & Case LLP
  • Elizabeth Gardner - Robins Kaplan LLP
  • Melvin C Garner - Leason Ellis LLP
  • Frank M Gasparo - Venable LLP
  • Vishal C Gupta - Steptoe & Johnson LLP
  • Mark Hannemann - Shearman & Sterling LLP
  • Christopher J Harnett - Jones Day
  • Pablo D Hendler - Jones Day
  • Benjamin Hershkowitz - Gibson Dunn & Crutcher LLP
  • Philip Hirschhorn - Buchanan Ingersoll & Rooney PC
  • Robert M Isackson - Leason Ellis LLP
  • Patrice P Jean - Hughes Hubbard & Reed LLP
  • Allan A Kassenoff - Greenberg Traurig LLP
  • Paul Keller - Norton Rose Fulbright US LLP
  • Gene W Lee - Perkins Coie LLP
  • Noah Leibowitz - Dechert LLP
  • Jane Love - Gibson Dunn & Crutcher LLP
  • Thomas R Makin - Shearman & Sterling LLP
  • William J McCabe - Perkins Coie LLP
  • Richard McCormick - Mayer Brown
  • John J Molenda - Steptoe & Johnson LLP
  • John Murnane - Venable LLP
  • Michael M Murray - Winston & Strawn LLP
  • Brian W Nolan - Mayer Brown
  • Catherine Nyarady - Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • Krishnan Padmanabhan - Winston & Strawn LLP
  • Thomas Parker - Alston & Bird LLP
  • Steven Pepe - Ropes & Gray LLP
  • Richard C Pettus - Greenberg Traurig LLP
  • Tony V Pezzano - DLA Piper LLP (US)
  • Filko Prugo - Ropes & Gray LLP
  • Michael N Rader - Wolf, Greenfield & Sacks, PC
  • Joshua L Raskin - Greenberg Traurig LLP
  • Preston K Ratliff II - Paul Hastings LLP
  • Daniel L Reisner - Arnold & Porter Kaye Scholer LLP
  • Brian Rosenthal - Gibson Dunn & Crutcher LLP
  • P Anthony Sammi - Skadden Arps Slate Meagher & Flom LLP
  • Kenneth H Sonnenfeld - King & Spalding LLP
  • Eric Stone - Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • Arun Subramanian - Susman Godfrey LLP
  • James Trainor - Fenwick & West LLP
  • Robert W Trenchard - Gibson Dunn & Crutcher LLP
  • Francisco A Villegas - Cohen & Gresser LLP
  • Baldassare Vinti - Proskauer Rose LLP
  • Scott T Weingaertner - White & Case LLP
  • Jennifer H Wu - Paul, Weiss, Rifkind, Wharton & Garrison LLP
  • Vanessa Yen - King & Spalding LLP
  • Michael T Zoppo - Fish & Richardson

Individuals: prosecution

  • Samuel B Abrams - Dechert LLP
  • Adriane M Antler - Jones Day
  • Jonathan D Ball - Greenberg Traurig LLP
  • Elizabeth Barnhard - Leason Ellis LLP
  • Samuel Borodach - Fish & Richardson
  • Jack Brennan - Fish & Richardson
  • Margaret Brivanlou - King & Spalding LLP
  • Daniel R Brownstone - Fenwick & West LLP
  • Laura C Brutman - Schiff Hardin LLP
  • Susie S Cheng - Leason Ellis LLP
  • Michael A Davitz - Leason Ellis LLP
  • Ivor R Elrifi - Cooley LLP
  • Melvin C Garner - Leason Ellis LLP
  • Joseph M Guiliano - Haley Guiliano LLP
  • James F Haley Jr - Haley Guiliano LLP
  • Daniel Hulseberg - Baker Botts LLP
  • David Leason - Leason Ellis LLP
  • Ying Li - Steptoe & Johnson LLP
  • Janet MacLeod - Fox Rothschild LLP
  • Karen Mangasarian - Foley & Lardner LLP
  • Michael Mercanti - Lucas & Mercanti LLP
  • Paul Ragusa - Baker Botts LLP
  • Pejman Sharifi - Winston & Strawn LLP
  • Deborah A Somerville - Fox Rothschild LLP
  • Kenneth H Sonnenfeld - King & Spalding LLP
  • Clifford A Ulrich - Hunton Andrews Kurth LLP

Individuals: transactions

  • Garrard R Beeney - Sullivan & Cromwell LLP 
  • Michael A Epstein - Weil Gotshal & Manges LLP
  • David J Kappos - Cravath, Swaine & Moore LLP 
  • Lori Lesser - Simpson Thacher & Bartlett LLP
  • Stuart D Levi - Skadden Arps Slate Meagher & Flom LLP
  • Jeffrey Osterman - Weil Gotshal & Manges LLP
  • Kenneth Rubenstein - Proskauer Rose LLP
  • Charan J Sandhu - Weil Gotshal & Manges LLP
  • Charles A Weiss - Holland & Knight LLP
  • Jordan Altman - Shearman & Sterling LLP
  • Mehdi Ansari - Sullivan & Cromwell LLP 
  • Elizabeth Barnhard - Leason Ellis LLP
  • Adam Chernichaw - White & Case LLP
  • Jennifer B Coplan - Sidley Austin LLP
  • Ivor R Elrifi - Cooley LLP
  • Jose A Esteves - Skadden Arps Slate Meagher & Flom LLP
  • John Evangelakos - Sullivan & Cromwell LLP 
  • Adam H Golden - Hogan Lovells
  • Bruce J Goldner - Skadden Arps Slate Meagher & Flom LLP
  • Daryn A Grossman - Proskauer Rose LLP
  • Arlene Hahn - White & Case LLP
  • Daniel Hulseberg - Baker Botts LLP
  • Jeffrey C Johnson - Pryor Cashman LLP
  • David Leason - Leason Ellis LLP
  • Michael J Lennon - Hunton Andrews Kurth LLP
  • David MacDonald - Kirkland & Ellis LLP
  • Thomas Pease - Quinn Emanuel Urquhart & Sullivan LLP
  • Paul Ragusa - Baker Botts LLP
  • Harry Rubin - Kramer Levin Naftalis & Frankel LLP
  • Alicia Russo - Venable LLP
  • Resa K Schlossberg - Skadden Arps Slate Meagher & Flom LLP
  • Pejman Sharifi - Winston & Strawn LLP
  • Kenneth H Sonnenfeld - King & Spalding LLP
  • Samuel Waxman - Paul Hastings LLP
  • Matthew B Zisk - Skadden Arps Slate Meagher & Flom LLP


  • Jesse J Jenner - Ropes & Gray LLP